Cherchez une société par raison sociale, ticker ou ISIN, puis ouvrez sa fiche.
Performance
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; and other oncology programs, such as solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
En 2025, l’exercice se solde par une perte de 51 M $US. Le flux de trésorerie libre, lui, s’établit à -45,7 M $US.
Le nombre d’actions est passé de 22,2 M à 32,3 M entre 2021 et 2025, soit 45,9 % de titres en plus : le bénéfice se partage entre davantage de parts.